Intellia Therapeutics Announces New Positive Clinical Data from Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema (HAE)
11 juin 2023 08h30 HE
|
Intellia Therapeutics, Inc.
Extended Phase 1 data reinforce the potential of NTLA-2002 to be a functional cure for people living with hereditary angioedema (HAE)Across all patients (n=10), a single dose of NTLA-2002 led to a 95%...
Intellia Therapeutics Announces Retirement of Jean-François Formela, M.D. From its Board of Directors
05 juin 2023 16h01 HE
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics...
Intellia Therapeutics to Present Updated Interim Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Hybrid Congress 2023
31 mai 2023 07h30 HE
|
Intellia Therapeutics, Inc.
Late-breaking presentation will include new safety, kallikrein reduction and attack rate data across all dose cohorts in the Phase 1 portion of the studyIntellia to host investor webcast on Monday,...
Intellia Therapeutics Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress
04 mai 2023 07h30 HE
|
Intellia Therapeutics, Inc.
Dosed first patient in the global Phase 2 study of NTLA-2002 for the treatment of hereditary angioedema (HAE)Expects to complete enrollment in the Phase 2 study of NTLA-2002 in 2H 2023Plans to submit...
Intellia Therapeutics Releases 2023 Corporate Responsibility Report Highlighting the Advancement of its Environmental, Social & Governance (ESG) Priorities
01 mai 2023 07h30 HE
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., May 01, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies...
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2023 Earnings and Company Updates
27 avr. 2023 07h30 HE
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative...
Intellia Therapeutics Names Bill Chase to its Board of Directors
17 avr. 2023 16h01 HE
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., April 17, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies...
Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to NTLA-2002 for the Treatment of Hereditary Angioedema
21 mars 2023 07h30 HE
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies...
Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for NTLA-2002, an In Vivo CRISPR-Based Investigational Therapy for the Treatment of Hereditary Angioedema (HAE)
02 mars 2023 07h00 HE
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies...
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Company Progress
23 févr. 2023 07h30 HE
|
Intellia Therapeutics, Inc.
Initiated the global Phase 2 study of NTLA-2002, a CRISPR-based, potential single-dose treatment for hereditary angioedema (HAE)Submitted IND application for NTLA-2002 to enable patient enrollment in...